- Home
- ROMA vs MIRA Comparison
ROMA vs MIRA Comparison
Compare ROMA & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROMA | MIRA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.5M | 33.7M |
| IPO Year | 2024 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ROMA | MIRA |
|---|---|---|
| Price | $1.56 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.4K | ★ 240.6K |
| Earning Date | 12-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,640,101.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.60 | N/A |
| 52 Week Low | $0.58 | $0.73 |
| 52 Week High | $4.66 | $2.45 |
Technical Indicators
Market Signals| Indicator | ROMA | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 18.36 | 49.50 |
| Support Level | $1.34 | $1.44 |
| Resistance Level | $1.75 | $1.51 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 8.21 | 20.00 |
Price Performance
Historical ComparisonAbout ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.